-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634.O1.6 634. Myeloproliferative Syndromes: Clinical: Emerging Therapies and Prognostic Scoring in Myelofibrosis and Other MPNs

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adult, Diseases, MPN, Study Population, Myeloid Malignancies
Monday, December 3, 2018: 10:30 AM-12:00 PM
Grand Hall A (Manchester Grand Hyatt San Diego)
Moderators:
Francesco Passamonti, MD, Ospedale Di Circolo E Fondazione Macchi and Kim-Hien Dao, DO, PhD, Oregon Health & Science University
Disclosures:
Dao: Incyte: Consultancy, Research Funding.
10:30 AM

John Mascarenhas, MD1, Rami S. Komrokji, MD2, Michele Cavo, MD3*, Bruno Martino, MD4*, Dietger Niederwieser, MD5, Andreas Reiter, MD6*, Bart L Scott, MD7, Maria R. Baer, MD8, Ronald Hoffman, MD9, Olatoyosi Odenike, MD10, Jacqueline Bussolari, PhD11, Eugene Zhu, PhD11*, Fei Huang, PhD12, Esther Rose, MD11*, Laurie Sherman, BSN12, Souria Dougherty, BS, MBA12*, Faye M. Feller, MD11 and Jean-Jacques Kiladjian, MD, PhD13

1Icahn School of Medicine at Mount Sinai, New York, NY
2Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL
3”Seràgnoli” Institute of Hematology Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
4Hematology Department, Grande Ospedale Metropolitano-G.O.M. Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
5Department of Hematology and Oncology, University Hospital Leipzig, Leipzig, Germany
6Department of Hematology and Oncology, University Hospital Mannheim, Mannheim, Germany
7Fred Hutchinson Cancer Research Center, Seattle, WA
8University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
9Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
10Section of Hematology/Oncology, University of Chicago, Chicago, IL
11Janssen Research & Development, LLC, Raritan, NJ
12Janssen Research & Development, LLC, Spring House, PA
13Centre d’Investigations Cliniques, Hôpital Saint-Louis, Université Paris Diderot, Paris, France

10:45 AM

Srdan Verstovsek, MD, PhD1, Robert P. Hasserjian, MD2, Olga Pozdnyakova, MD, PhD3*, Ivo Veletic, MD4*, Ruben A. Mesa, MD5, Lynda Foltz, MD, FRCPC6, John Mascarenhas, MD7, Ellen K. Ritchie, MD8, Jeanne Palmer, MD9, Richard T. Silver, MD8, Marina Kremyanskaya, MD, PhD10*, Bernt van den Blink, MD, PhD11*, Renu Gupta, MD11*, Taghi Manshouri, PhD4*, C. Cameron Yin, MD, PhD12, Zeev E. Estrov, MD1 and Jason R. Gotlib, MD, MS13

1Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Pathology, Massachusetts General Hospital, Boston, MA
3Brigham and Women's Hospital, Boston, MA
4The University of Texas MD Anderson Cancer Center, Houston, TX
5UT Health San Antonio Cancer Center, San Antonio, TX
6St Paul’s Hospital, University of British Columbia, Vancouver, BC, Canada
7Icahn School of Medicine at Mount Sinai, New York, NY
8Weill Cornell Medicine, New York, NY
9Division of Hematology and Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ
10Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
11Promedior, Inc., Lexington, MA
12Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
13Department of Medicine, Stanford University School of Medicine, Stanford, CA

11:00 AM

Naveen Pemmaraju, MD1, Bing Z Carter, PhD2, Hagop M. Kantarjian, MD3, Jorge E. Cortes, MD3*, Tapan M. Kadia, MD4, Guillermo Garcia-Manero, MD5, Courtney D. DiNardo, MD, MSc6, Prithviraj Bose, MD7, Naval G. Daver, MD7, Marina Y. Konopleva, MD, PhD7, Maro N. Ohanian, DO3, Sherry A. Pierce, BSN, BA3*, Lingsha Zhou3*, Zeev E. Estrov, MD5, Gautam Borthakur, MD3, Karina Salinas, RN8*, Po Yee Mak9*, Nitin Jain, MD7, Elias J. Jabbour, MD 5 and Srdan Verstovsek, MD, PhD4

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Bellaire, TX
2Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX
5Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
6Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
7Department of Leukemia, MD Anderson Cancer Center, Houston, TX
8Leukemia Department, MD Anderson Cancer Center, Houston, TX
9Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

11:15 AM

Naseema Gangat, MBBS1, Brady Lee Stein, MD2, Christian Marinaccio3*, Ronan Swords, MD, PhD4, Justin M. Watts, MD5, Sandeep Gurbuxani6, Olga Frankfurt, MD7*, Jessica K. Altman, MD8, Jeremy Q. Wen, MD, PhD9*, Noushin Farnoud, PhD10*, Christopher Famulare, MS11*, Akshar Patel, BA12*, Roberto Tapia, BS13, Amy Handlogten14*, Yvonne Trang Dinh, BS15*, Kristen Englund15*, Shradha Patel16*, Juan Carlos Nobrega16*, Dalissa Tejera, MSN15*, Amber Thomassen16*, Harald Stein, MD, PhD, Dr. h.c.17*, Juehua Gao, MD, PhD18*, Peng Ji, MD, PhD,19, Raajit K. Rampal, MD, PhD20, Francis J. Giles, MD, FRCPI, FRCPath21, Ayalew Tefferi, MD1 and John D. Crispino, PhD, MBA22

1Division of Hematology, Mayo Clinic, Rochester, MN
2Dept. of Medicine, Division of Hematology/Oncology and Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
3Northwestern University, Chicago, IL
4University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL
5Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, FL
6The University of Chicago, Chicago, IL
7Northwestern Memorial Hospital, Chicago, IL
8Northwestern Univ., Chicago, IL
9Hematology and Oncology, Chicago, IL
10Center for Molecular Oncology and Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
11Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
12Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY
13Division of Hematology/Oncology, Northwestern University, Chicago, IL
14Mayo Clinic, Rochester, MN
15University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
16Sylvester Cancer Center, University of Miami, Miami, FL
17Universitätsklinikum Benjamin Franklin Institut für Pathologie, Berlin, DEU
18Department of Pathology, Northwestern University, Chicago, IL
19Northwestern University, Feinberg School of Medicine, Chicago, IL
20Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Myeloproliferative Neoplasm Research Consortium (MPN-RC), New York, NY
21Northwestern Medicine Developmental Therapeutics Institute, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
22Division of Hematology and Oncology, Northwestern University, Chicago, IL

11:30 AM

Nico Gagelmann1*, Markus Ditschkowski2*, Rashit Bogdanov2*, Marie Robin, MD, PhD3, Bruno Cassinat, PharmD, PhD4*, Michael Heuser, MD5, Rabia Shahswar5*, Felicitas Thol, MD5, Dietrich W. Beelen6, Anita Badbaran1* and Nicolaus Kroeger7

1Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Essen, Essen, Germany
3Department of Hematology, Saint-Louis Hospital, AP-HP, Paris, France
4Laboratoire de Biologie Cellulaire, APHP, Hôpital Saint-Louis, Paris, France
5Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Hannover, Germany
6Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany
7Department of Stem Cell Transplantation, University Hospital Eppendorf, Hamburg, Germany

11:45 AM

Srdan Verstovsek, MD, PhD1, Alessandro M. Vannucchi, MD2, Alessandro Rambaldi, MD, PhD3*, Jason R. Gotlib, MD, MS4, Adam J. Mead, MD, PhD5, Andreas Hochhaus, MD6,7, Jean-Jacques Kiladjian, MD, PhD8, Juan Carlos Hernandez Boluda, MD, PhD9*, Ekaterine Asatiani, MD10, Christine Lihou, BS10*, Huiling Zhen, MD, PhD10* and Andreas Reiter, MD11*

1Department of Leukemia, University of Texas M.D. Anderson Cancer Center, Houston, TX
2Azienda Ospedaliero Universitaria Careggi, Firenze, ITA
3University of Milan and Azienda Socio Sanitaria Territoriale, Papa Giovanni XXIII, Bergamo, Italy
4Stanford Cancer Institute, Stanford, CA
5Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
6Klinik für Innere Medizin II, Jena, Germany
7Univerisitätsklinikum Jena, Jena, Germany
8Hôpital Saint-Louis, Paris, France
9Hospital Clínico Universitario, Valencia, Spain
10Incyte Corporation, Wilmington, DE
11Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany

*signifies non-member of ASH